Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 196

1.

Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.

Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B.

Breast Cancer Res. 2017 Nov 14;19(1):120. doi: 10.1186/s13058-017-0911-9.

2.

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.

Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, Villanueva C, Jakobsen E, Alba E, Wist E, Favret AM, Bachelot T, Hegg R, Wheatley-Price P, Souami F, Sutradhar S, Miller M, Germa C, Burris HA.

Breast Cancer Res Treat. 2018 Feb;167(3):659-669. doi: 10.1007/s10549-017-4523-y. Epub 2017 Oct 22.

3.

Erratum: Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer.

Vaysse C, Lømo J, Garred Ø, Fjeldheim F, Lofteroed T, Schlichting E, McTiernan A, Frydenberg H, Husøy A, Lundgren S, Fagerland MW, Richardsen E, Wist EA, Muller C, Thune I.

NPJ Breast Cancer. 2017 Sep 5;3:35. doi: 10.1038/s41523-017-0030-x. eCollection 2017.

4.

Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013.

Kvåle R, Myklebust TÅ, Engholm G, Heinävaara S, Wist E, Møller B.

Int J Cancer. 2017 Dec 1;141(11):2228-2242. doi: 10.1002/ijc.30924. Epub 2017 Aug 26.

PMID:
28795403
5.

Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer.

Vaysse C, Lømo J, Garred Ø, Fjeldheim F, Lofteroed T, Schlichting E, McTiernan A, Frydenberg H, Husøy A, Lundgren S, Fagerland MW, Richardsen E, Wist EA, Muller C, Thune I.

NPJ Breast Cancer. 2017 May 3;3:19. doi: 10.1038/s41523-017-0015-9. eCollection 2017. Erratum in: NPJ Breast Cancer. 2017 Sep 5;3:35.

6.

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.

Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group.

Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16.

PMID:
28625777
7.

The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL, Engebraaten O.

Clin Cancer Res. 2017 Aug 15;23(16):4662-4670. doi: 10.1158/1078-0432.CCR-17-0160. Epub 2017 May 9.

PMID:
28487444
8.

Fatigue During and After Breast Cancer Therapy-A Prospective Study.

Reinertsen KV, Engebraaten O, Loge JH, Cvancarova M, Naume B, Wist E, Edvardsen H, Wille E, Bjøro T, Kiserud CE.

J Pain Symptom Manage. 2017 Mar;53(3):551-560. doi: 10.1016/j.jpainsymman.2016.09.011. Epub 2016 Dec 29.

PMID:
28042070
9.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J.

N Engl J Med. 2016 Nov 3;375(18):1738-1748. Epub 2016 Oct 7.

10.

Polymorphisms in the estrogen receptor alpha gene (ESR1), daily cycling estrogen and mammographic density phenotypes.

Fjeldheim FN, Frydenberg H, Flote VG, McTiernan A, Furberg AS, Ellison PT, Barrett ES, Wilsgaard T, Jasienska G, Ursin G, Wist EA, Thune I.

BMC Cancer. 2016 Oct 7;16(1):776.

11.

Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer.

Flote VG, Vettukattil R, Bathen TF, Egeland T, McTiernan A, Frydenberg H, Husøy A, Finstad SE, Lømo J, Garred Ø, Schlichting E, Wist EA, Thune I.

Lipids Health Dis. 2016 Mar 12;15:56. doi: 10.1186/s12944-016-0225-4.

12.

Aspects of posttraumatic stress disorder in long-term testicular cancer survivors: cross-sectional and longitudinal findings.

Dahl AA, Østby-Deglum M, Oldenburg J, Bremnes R, Dahl O, Klepp O, Wist E, Fosså SD.

J Cancer Surviv. 2016 Oct;10(5):842-9. doi: 10.1007/s11764-016-0529-4. Epub 2016 Feb 26.

PMID:
26920871
13.

Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival.

Frydenberg H, Thune I, Lofterød T, Mortensen ES, Eggen AE, Risberg T, Wist EA, Flote VG, Furberg AS, Wilsgaard T, Akslen LA, McTiernan A.

Breast Cancer Res Treat. 2016 Jan;155(2):345-54. doi: 10.1007/s10549-015-3671-1. Epub 2016 Jan 6.

PMID:
26740213
14.

High-density lipoprotein-cholesterol, daily estradiol and progesterone, and mammographic density phenotypes in premenopausal women.

Flote VG, Frydenberg H, Ursin G, Iversen A, Fagerland MW, Ellison PT, Wist EA, Egeland T, Wilsgaard T, McTiernan A, Furberg AS, Thune I.

Cancer Prev Res (Phila). 2015 Jun;8(6):535-44. doi: 10.1158/1940-6207.CAPR-14-0267. Epub 2015 Mar 24.

15.

Gene variations in oestrogen pathways, CYP19A1, daily 17β-estradiol and mammographic density phenotypes in premenopausal women.

Flote VG, Furberg AS, McTiernan A, Frydenberg H, Ursin G, Iversen A, Lofteroed T, Ellison PT, Wist EA, Egeland T, Wilsgaard T, Makar KW, Chang-Claude J, Thune I.

Breast Cancer Res. 2014 Dec 19;16(6):499. doi: 10.1186/s13058-014-0499-2.

16.

Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.

Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Sætersdal AB, Rypdal MC, Bendigtsen Schirmer C, Wist EA, Borgen E.

J Clin Oncol. 2014 Dec 1;32(34):3848-57. doi: 10.1200/JCO.2014.56.9327. Epub 2014 Nov 3.

PMID:
25366688
17.

A randomized clinical trial of the efficacy of a self-care intervention to improve cancer pain management.

Rustøen T, Valeberg BT, Kolstad E, Wist E, Paul S, Miaskowski C.

Cancer Nurs. 2014 Jan-Feb;37(1):34-43. doi: 10.1097/NCC.0b013e3182948418.

PMID:
23666269
18.

Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study.

Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, Boyages J, Christiansen P, Lee M, Wärnberg F, Allemani C, Engholm G, Fornander T, Gjerstorff ML, Johannesen TB, Lawrence G, McGahan CE, Middleton R, Steward J, Tracey E, Turner D, Richards MA, Coleman MP; ICBP Module 1 Working Group.

Br J Cancer. 2013 Mar 19;108(5):1195-208. doi: 10.1038/bjc.2013.6. Epub 2013 Feb 28.

19.

Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.

Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B.

BMC Cancer. 2012 Dec 22;12:616. doi: 10.1186/1471-2407-12-616.

20.

Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer.

Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Bjøro T, Wentzel-Larsen T, Dahl O; Norwegian Urology Cancer Group (NUCG) III study group.

Br J Cancer. 2012 Nov 20;107(11):1833-9. doi: 10.1038/bjc.2012.471.

Supplemental Content

Loading ...
Support Center